Welcome Back |Sign in | Register
Your Position: Home > Inhibitors/Agonists > MK-8722

View History

MK-8722
prev zoom next

Name:MK-8722

  • Catalog No.:
  • BCM006687
  • Chem Name:
  • (3R,3aR,6R,6aR)-6-[[6-chloro-5-(4-phenylphenyl)-1H-imidazo[4,5-b]pyridin-2-yl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol
  • Synonym:
  • MK-8722; MK8722; MK 8722
  • CAS No.:
  • 1394371-71-1
  • MDL No.:
  • MFCD31715423
  • Formula:
  • C24H20ClN3O4
  • Molecular:
  • 449.89
  • Form:
  • White to Off-White Solid
  • Storage:
  • Sealed in dry, 2-8°C
  • Wish  | Compare  | Referral bonuses
SKU Specification Brand Prices Stock Quantity Cart
BCM006687-5MG 5mg, Purity:98% BCM $120 2 Add Cart
BCM006687-10MG 10mg, Purity:98% BCM $199 2 Add Cart
BCM006687-50MG 50mg, Purity:98% BCM $710 2 Add Cart
For more quantities, please contact telephone:0755-85269922,Or send an email to:sales@biochemmall.com

Product Description

Attribute

Goods Tag

Related Products

 

MK-8722 is a potent, direct, allosteric activator of all 12 mammalian pan-AMPK complexes.

 

Brand: BCM

 

Melting Point: 215 - 219°C

 

Boiling Point: 716.6±70.0 °C(Predicted)

 

pKa: 8.22±0.40(Predicted)

 

Stability: Hygroscopic

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

GHS: GHS07

 

In Vitro: 

MK8722 is an effective, direct, allosteric activator of all 12 mammalian AMPK complexes. pAMPK activation by maximal AMP plus MK8722 is synergistic, demonstrating that the agents act at distinct sites. MK8722 activates pAMPK complexes with increased potency and magnitude versus AMP (EC50: ~1 to 60 nM) and increased activation by factors of ~4 to 24. Although MK8722 exhibits a higher affinity for β1-containing (~1 to 6 nM) versus β2-containing (~15 to 63 nM) pAMPK complexes, it is the most potent activator of β2 complexes reported to date .

 

In Vivo:

MK8722(once-daily)administration, causes dose-dependent lowering of ambient blood glucose. 
Chronic MK8722 dosing in mice also increases muscle Glut4 protein levels, possibly contributing to efficacy. Chronic antihyperglycemic efficacy of MK8722 is evaluated in db/db  
mice (a leptin receptor-deficient T2DM model). 
Glucose reductions after MK8722 treatment (30 mpk/day) are comparable to those observed with the PPARγ agonist BRL49653 (3 mpk/day), on treatment day 12. 
Dose-dependent enhances in tissue pACC are maintained throughout the dosing period. 
Chronic efficacy, without tachyphylaxis, is also observed in additional dysmetabolic and diabetic rodent models.
In all cases, efficacy is associated with trough MK8722 plasma levels comparable to the concentrations required to acutely stimulate skeletal muscle glucose uptake. The glucose-lowering action of MK8722 manifests without significant effects on body weight . 

 

Isomeric SMILES: C1[C@H]([C@@H]2[C@H](O1)[C@@H](CO2)OC3=NC4=NC(=C(C=C4N3)Cl)C5=CC=C(C=C5)C6=CC=CC=C6)O  

 

InChIKey: XQMNBTZLYOOAGA-UGESXGAOSA-N  

 

InChI: InChI=1S/C24H20ClN3O4/c25-16-10-17-23(28-24(26-17)32-19-12-31-21-18(29)11-30-22(19)21)27-20(16)15-8-6-14(7-9-15)13-4-2-1-3-5-13/h1-10,18-19,21-22,29H,11-12H2,(H,26,27,28)/t18-,19-,21-,22-/m1/s1 

 

Attribute
[Chem Name] (3R,3aR,6R,6aR)-6-[[6-chloro-5-(4-phenylphenyl)-1H-imidazo[4,5-b]pyridin-2-yl]oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol
[Synonym] MK-8722; MK8722; MK 8722
[CAS No.] 1394371-71-1
[MDL No.] MFCD31715423
[Formula] C24H20ClN3O4
[Molecular] 449.89
[Form] White to Off-White Solid
[Storage] Sealed in dry, 2-8°C

Goods Tag

User Comment(Total0User Comment Num)

  • No comment
Total 0 records, divided into1 pages. First Prev Next Last
Username: Anonymous user
E-mail:
Rank:
Content:
Verification code: captcha